Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Joblessness Surprise ↗
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
News headline image
“Claw-Back” day ↗
The rally was just as irrational as the selloff. 
Via Talk Markets
News headline image
Delta Defeats Bulls ↗
Stocks tended to crash without rhyme or reason. 
Via Talk Markets
News headline image
Weak Week ↗
Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism. 
Via Talk Markets
News headline image
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News ↗
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ... 
Via Benzinga
News headline image
Dialing For Stocks ↗
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
News headline image
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients ↗
Biogen Inc. (NASDAQ:BIIB) shares are lower after the compa... 
Via Benzinga
News headline image
People Needed ↗
If qualified people are not looking for work, they will have to be lured to do so with higher wages. 
Via Talk Markets
News headline image
End Of June ↗
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Summer Friday ↗
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
News headline image
Crazy Thursday ↗
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
News headline image
Wednesday Is A Normal Day ↗
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
The First Day Of Summer And Prime Day ↗
The bull is back in business today. 
Via Talk Markets
News headline image
3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations ↗
Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week. 
Via The Motley Fool
News headline image
Did This Company Just Win Big Because of Biogen? ↗
Alzheimer's disease patients who take Aduhelm will need a lot of diagnostic scans, too. Imaging leader RadNet stands to benefit. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights ↗
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
News headline image
Two Rate Hikes In 2023 ↗
This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard. 
Via Talk Markets
Topics Economy
News headline image
Continued Uncertainty ↗
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
News headline image
Dreary Day ↗
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
News headline image
Happy Friday ↗
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
News headline image
Unheeding Markets ↗
Today oil prices rose over $70. 
Via Talk Markets
News headline image
Wednesday News And Catch-Up ↗
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
News headline image
FDA surprise ↗
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
News headline image
Biogen's Alzheimer's Disease Treatment Earns FDA Approval ↗
Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories. 
Via The Motley Fool
News headline image
Why Biogen Stock Is On Fire Today ↗
The biotech's controversial Alzheimer's disease drug got a green light from the FDA. 
Via The Motley Fool
News headline image
Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib ↗
Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab... 
Via Benzinga
News headline image
A Better Switch ↗
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.